Please assess the completion status of the following clinical trial:

Trial Title: Local Phase IV, Gastroesophageal Reflux Disease (GERD) Sleep Study US

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Prior to the run-in period, a history of heartburn or acid regurgitation for 3 months or longer or any history of EE;~* Prior to the run-in period, nighttime heartburn averaging at least 2 or 3 times per week;~* Prior to the run-in period, a history of sleep disturbances associated with GERD for 1 month or more;~Exclusion Criteria:~* Any condition other than GERD that is either the primary cause of, or a significant contributor to, the patient's sleep disturbance~* Sleep medication (including over-the-counter), antihistamine, benzodiazepine, or anti-anxiety medication use that has not been stable (either in dose or regularity) for at least 3 months or is not expected to remain stable during the patient's participation in the study. Patients on a stable regimen, whose regimen is also expected to remain stable throughout the study, are eligible for participation;~* Proton Pump Inhibitor (PPI) use within 1 week prior to Screening. The only allowable acid modifying rescue medication is GELUSIL® during the run-in period. Only study medication and rescue medication (GELUSIL®) is allowed during the treatment period for treatment of acid mediated symptoms

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Nexium 20mg (Type: EXPERIMENTAL): Nexium 20 mg administered once daily as 22.3 mg of esomeprazole magnesium hydrate
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).